Polymyxin B and rifampin were given to 12 patients with multi-drug-resistant nosocomial Serratia marcescens infections. Eight cures were achieved; drug hepatotoxicity occurred once; one fatal suprainfection was encountered; and two patients died during therapy of causes related to severe underlying illnesses. Polymyxin B and rifampin were uniformly synergistic in vitro against the infecting strains and against 40 additional clinical isolates ofS. marcescens.
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Serratia marcescens has become established as an important nosocomial pathogen in recent years (3, 8) . The upsurge in infections due to this bacterium, previously considered to be of low virulence, is reminiscent of the phenomenon noted earlier in the antibiotic era with Pseudomonas aeruginosa because many nosocomial Serratia are resistant to antibiotics commonly used in hospital practice. An endemic involving multiresistant Serratia at the Little Rock Veterans Administration Hospital (LRVAH) necessitated development of a novel therapeutic regimen. Polymyxin B and rifampin are synergistic in vitro for this species (12, 14) but have not been used together in patients. This study was consequently undertaken to evaluate the extent of antibiotic resistance among Serratia at LRVAH, to determine their susceptibility to polymyxin B and rifampin, and to assess the efficacy and toxicity of therapy with polymyxin B and rifampin in patients seriously ill with infections due to multiresistant Serratia.
MATERIALS AND METHODS
Patient selection. During a 5-month period, from May through September 1976, all patients seen in consultation by the Infectious Disease Service at LRVAH who met all the following criteria were treated with polymyxin B and rifampin: (i) presence of a local infection characterized by symptoms and signs typical of bacterial infection in that site, a systemic response of fever, leukocytosis and change in general well-being, and isolation of Serratia in pure culture from involved tissue or fluid (except in respiratory tract infections, for which the criteria of Tillotson and Finland [13] In vitro studies. The Serratia isolate from each patient was tested for susceptibility to polymyxin B and rifampin by a standard two-dimensional brothdilution checkerboard technique (10) . The studies were performed in brain heart infusion broth inoculated with 105 colony-forming units. Previous definitions for synergy in this system were used (15), but, in addition, an organism was considered susceptible only if.the minimal inhibitory concentration (MIC) of the more active antibiotic in the combination occurred at a concentration less than onehalf that of drug that could be expected in serum after administration of the doses used for treating patients.
Growth-curve experiments (5) give a concentration of 10' colony-forming units/ml. The five inhibitory end points thus derived after overnight incubation were used to construct a modified isobologram consisting of the MIC for each antibiotic alone and those for the two drugs mixed together in concentration ratios of 2:1, 1:1, and 1:2. These isobolograms easily permitted an assessment of synergy by standard criteria. The microtiter system was also used to determine the susceptibility of these 40 Serratia isolates to gentamicin, amikacin, and chloramphenicol.
RESULTS
Outcome of therapy with polymyxin B and rifampin. Fourteen patients met the criteria for treatment with polymyxin B and rifampin; all were treated. Two cases were not evaluated because protocol for drug administration was not followed; in one instance, the patient was not cooperative, and, in the other, the supervising physician inadvertently amended the regimen. Limited follow-up of these two cases did not reveal evidence of treatment failure or drug toxicity.
The 12 Serratia infections we could evaluate included five that were bacteremic (Table 1) . Eleven patients had significant underlying illnesses, and a like number received antibiotic therapy before treatment with polymyxin B and rifampin. Intravenous devices were present in 10 patients and bladder catheters in 7 when infection was diagnosed.
A total of 8 (67%) of the 12 cases, including all 5 patients with Serratia bacteremia, had favorable responses and were cured clinically and bacteriologically. These infections responded to polymyxin B and rifampin with prompt defervescence, with resolution of other signs of sepsis, and with appropriate amelioration of local infection. Therapy was terminated after 10 days in all responders except patient 11, who had osteomyelitis and received therapy for 6 weeks. Three patients died while receiving polymyxin B-rifampin therapy. Treatment of the infection was progressing satisfactorily in two (patients 8 and 10), but the patients succumbed to severe underlying illnesses. The other fatal case (patient 12) was related to suprainfection with Proteus mirabilis at the original Serratia infection site. Drug toxicity was encountered in one patient (case 7); jaundice and abnormal liver function studies were noted on day 3 of therapy and regressed promptly when antibiotics were discontinued. One patient (case 1 and 9) was treated for two distinct Serratia infections. He developed Serratia pneumonia and was cured, but 2 weeks later acquired, and was successfully treated for, septic thrombophlebitis, a bacteremic illness associated with an intravenous catheter. In the interim period, Serratia was not present in any culture.
In vitro synergy of polymyxin B and rifampin against Serratia. All infecting strains were moderately resistant to rifampin (all MIC values were greater than 6.25 ,ug/ml) and highly resistant to polymyxin B (all MIC values were greater than 100 ,ug/ml). However, when combined in the checkerboard studies, the antibiotics acted synergistically against all 12 strains from infected patients. An isobologram derived from a representative study is depicted in Fig.  1 . These results were confirmed by those of growth-curve studies. Antibiotic concentra- VOL. 12, 1977 on June 23, 2017 by guest http://aac.asm.org/ Downloaded from tions attainable in serum (5 ,ug/ml) sterilized broth cultures of four infecting strains within 24 h, whereas that concentration of each drug alone had no influence on growth of the bacteria (Fig. 2) . Only ten (19%) of these 52 Serratia strains were inhibited by 6.3 ,ug of gentamicin per ml, a concentration attainable in serum. Susceptibility to chloramphenicol among these isolates was also low (12%), but all 52 isolates were susceptible to 6.3 g of amikacin per ml.
DISCUSSION
The present study confirns previous reports of polymyxin B and rifampin synergy against Serratia (12, 14) and extends those observations by demonstrating the efficacy of polymyxin B and rifampin in serious Serratia infections. Three of the four patients who failed to respond to polymyxin B and rifampin had severe underlying illnesses, an established risk factor in the treatment of gram-negative bacillary infections (6) . Drug toxicity was a major concern in the use of polymyxin B and rifampin in elderly patients with a variety of preexisting illnesses, but careful monitoring revealed only one instance, and in that case the signs of hepatic dysfunction regressed promptly upon withdrawal of drugs.
Gentamicin has been considered the drug of choice for infections due to Serratia. However, recent nosocomial outbreaks have been characterized by resistance to gentamicin and to most other antibiotics appropriate to treat systemic infection. The current rate of Serratia resistance to gentamicin at LRVAH is 81%. Accordingly, it would no longer be wise to choose gentamicin empirically in a nosocomial infection due to Serratia unless in vitro testing showed that the isolate was susceptible.
Amikacin, a new aminoglycoside antibiotic, has excellent potential for use in infections such as those treated in the present study. Most aerobic gram-negative bacilli that are resistant to gentamicin are susceptible to amikacin, and clinical trials have proved the value of this drug in infections caused by organisms resistant to gentamicin, including Serratia (7, 11) . We presently consider amikacin as the drug of choice for multiresistant Serratia infections. However, three recent articles report resistance emerging to amikacin during treatment of Serratia and P. aeruginosa infections with that antibiotic and concomitant clinical failure to cure the infection (1, 2, 9 ). Consequently, the availability of amikacin does not obviate the need for effective alternative therapy for infections ascribable to multiresistant nosocomial pathogens. Based on the encouraging results in this small, uncontrolled study, further evaluation of polymyxin B and rifam- 
